Voyager Therapeutics Inc
NASDAQ:VYGR
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.27
10.84
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VYGR stock under the Base Case scenario is 4.314 USD. Compared to the current market price of 5.655 USD, Voyager Therapeutics Inc is Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Voyager Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VYGR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Voyager Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Voyager Therapeutics Inc
Balance Sheet Decomposition
Voyager Therapeutics Inc
Current Assets | 373.4m |
Cash & Short-Term Investments | 345.4m |
Receivables | 19.7m |
Other Current Assets | 8.4m |
Non-Current Assets | 52.6m |
PP&E | 49.7m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 44.2m |
Accounts Payable | 3.2m |
Accrued Liabilities | 18.4m |
Other Current Liabilities | 22.6m |
Non-Current Liabilities | 51.5m |
Other Non-Current Liabilities | 51.5m |
Earnings Waterfall
Voyager Therapeutics Inc
Revenue
|
163.8m
USD
|
Operating Expenses
|
-151.9m
USD
|
Operating Income
|
11.9m
USD
|
Other Expenses
|
14m
USD
|
Net Income
|
25.9m
USD
|
Free Cash Flow Analysis
Voyager Therapeutics Inc
USD | |
Free Cash Flow | USD |
VYGR Profitability Score
Profitability Due Diligence
Voyager Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Voyager Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
VYGR Solvency Score
Solvency Due Diligence
Voyager Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Voyager Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VYGR Price Targets Summary
Voyager Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for VYGR is 17.567 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.
Dividends
Current shareholder yield for VYGR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VYGR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
Contact
IPO
Employees
Officers
The intrinsic value of one VYGR stock under the Base Case scenario is 4.314 USD.
Compared to the current market price of 5.655 USD, Voyager Therapeutics Inc is Overvalued by 24%.